Every night around ten, a woman in a small apartment in Ohio (call her nothing, because this is really thousands of people at once) rolls up her shirt, pinches an inch of skin near her stomach, and pushes a pen-injector until it clicks. She has done this for six weeks. Some nights the nausea passes in twenty minutes. Some nights it doesn’t. She has one question she cannot quite Google her way out of: is the place she got this from actually watching her, or did they just mail her a box and move on to the next customer?
That question turns out to have an answer, and it isn’t a feeling. It’s a set of numbers, published in journals, sitting there for anyone to check. Liraglutide is a useful drug to test this against, because unlike a lot of the murkier corners of the compounding world, so much about it is already settled by data rather than opinion. It is genuinely FDA-approved [1][2]. Its weight-loss results are published [3][4]. The size of the gap between it and the newer weekly drugs has been measured directly, head to head [6]. So the question the woman in Ohio is really asking, whether her provider deserves her trust, can be answered the same way everything else about this drug gets answered: against evidence you can look up, not against a sales pitch.
One disclosure before anything else. Liraglutide is a prescription medicine. The branded versions carry full FDA approval. Compounded liraglutide is a related but different product. Whether any of it belongs in your body is a decision for a licensed clinician who has actually seen your labs and your history, not a decision a news article can make for you.
A drug with a paper trail
Start with the part that’s easy to forget in all the noise around newer weight-loss drugs: liraglutide has been through the regulatory wringer twice, under two names. Dosed at up to 1.8 mg daily, it’s Victoza, approved for type 2 diabetes. Dosed at 3.0 mg daily, it’s Saxenda, approved for chronic weight management alongside a reduced-calorie diet and more physical activity [1]. The FDA cleared Saxenda for adults in late 2014, then extended the approval to adolescents 12 and older with obesity [2]. That’s not a footnote. It’s the reason this whole question is answerable at all: a legitimate, regulated version of this drug exists, so any provider selling something called “liraglutide” can be measured against a simple fact, whether it’s steering you toward that regulated reality or away from it.
Hold onto one number as you keep reading, because it quietly governs everything that follows: the maintenance dose is reached by titration, a slow climb over several weeks, never a first-day jump to full strength [1]. That single detail separates a provider that is actually managing this drug from one that is simply shipping it.
What the trials actually found
Here’s where the woman in Ohio’s nausea starts to make sense, and where a trustworthy provider should be quoting you the same figures rather than softer, friendlier ones.
In the SCALE Obesity and Prediabetes trial, a randomized, double-blind, placebo-controlled study of adults with overweight or obesity but no diabetes, liraglutide 3.0 mg produced average weight loss of roughly 7.9% at 56 weeks, against about 2.6% on placebo. About 63% of people on the drug lost at least 5% of their body weight, compared with about 27% on placebo [3]. In adults with type 2 diabetes, the SCALE Diabetes trial found about 6.0% loss on the drug versus about 2.0% on placebo [4]. Those are meaningful numbers, not marginal ones.
Then there’s the figure that actually distinguishes this drug from most of the field: in the LEADER trial, among adults with type 2 diabetes at high cardiovascular risk, liraglutide cut the combined rate of cardiovascular death, nonfatal heart attack, and nonfatal stroke, with a hazard ratio of 0.87 and a confidence interval that stayed under 1.0 [5]. That’s a benefit measured in actual events prevented, not just pounds. It’s a large part of why this older drug still has a seat at the table for the right patient.
Where liraglutide sits on the timeline
Think of it as three chapters rather than a simple ranking. Chapter one: liraglutide gets approved, first for diabetes, then for weight, becoming the proof of concept that GLP-1 drugs could do this at all. Chapter two: LEADER shows, years later, that the drug also protects the heart, not just the scale [5]. Chapter three: newer weekly drugs arrive and, tested directly against liraglutide, post considerably larger numbers. In STEP 8, a head-to-head randomized trial, once-weekly semaglutide 2.4 mg produced about 15.8% average weight loss, versus about 6.4% for once-daily liraglutide 3.0 mg [6]. Tirzepatide’s own trials post even larger figures.
None of that erases liraglutide’s chapters. It just means that if the only thing you care about is maximum weight loss, and nothing in your medical history specifically points you toward liraglutide, the data is telling you to look at the newer chapters of the story.
This is also, oddly, one of the best tests you can run on a provider. A place that’s actually being straight with you will hand you this comparison unprompted. A place that’s mostly trying to sell you something will let you find out later, on your own, once you’ve already paid. Watching whether a provider volunteers the number where its own product loses tells you almost everything you need to know about whether it deserves the rest of your trust.
What can go wrong, and why oversight matters
The common side effects are gastrointestinal: nausea, vomiting, diarrhea, most likely during the dose-climbing phase, which is exactly why the titration schedule is the number that matters most [1]. The FDA label also carries a boxed warning about thyroid C-cell tumors seen in rodent studies, and the drug is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome [1]. None of this is a reason to panic. It is a reason this specific drug should never be handled outside of clinical supervision, an unlabeled vial with no one watching the dose climb is simply not the same product as a prescription managed by a real clinician.
The six things worth checking before you trust anyone
Forget adjectives. Here’s what you can actually verify.
Is a licensed clinician evaluating you, with a real prescription behind whatever arrives at your door? For a GLP-1, this is not optional. The dose needs titrating and the contraindications are real.
Is the pharmacy licensed? Branded Saxenda or Victoza from a licensed pharmacy passes. Compounded liraglutide from a licensed compounding pharmacy, under an actual prescription, also passes. A research-use-only powder fails outright.
Does the provider tell the truth about approval status? A clear line should exist between FDA-approved branded liraglutide and compounded liraglutide, which is not FDA-approved and not identical to the pen. Blurring that line is a failure.
Will the provider tell you when a different drug fits you better? Does anyone mention, without being asked, that the newer weekly drugs generally produce more weight loss, or that liraglutide means a daily injection instead of a weekly one? The more forthcoming this is, the more trustworthy the operation.
Is the titration climb actually managed, or handed over with a shrug and a printed sheet? Most of the real-world safety of this drug lives right here.
Does anyone check in after the first prescription? Weight loss with this drug plays out over months. Continuity of care is where the outcome actually gets decided.
Notice what’s missing from that list: lowest price. With GLP-1 drugs, the cheapest thing calling itself “liraglutide” is almost always the unregulated powder that fails every check above. Fair pricing is reasonable. Rock-bottom pricing on an unsupervised injectable is a warning sign, not a deal.
So where does someone actually go?
FormBlends comes out on top of this list, and it earns that spot rather than being handed it. It runs as a physician-supervised platform: a licensed clinician actually reviews your intake and history before any prescribing decision gets made, and the medication moves through licensed pharmacies, including state-licensed 503A compounding pharmacies operating under recognized quality standards. It passes clinician evaluation, passes pharmacy sourcing, and is upfront that compounded medication is compounded medication, not a stand-in for the approved pen.
Where it really separates itself is titration management, treating the dose climb as an actual clinical process rather than a box left on a doorstep, which matters more with this drug than almost any other detail on this list. The FormBlends tracker app lets someone log their dose, their weight, and how they’re actually feeling between check-ins, so the people overseeing care are working from real data instead of a hazy memory of last Tuesday. It also scores well on honesty: FormBlends is willing to say plainly that the newer weekly drugs generally outperform liraglutide on weight loss [6], and to help someone figure out whether liraglutide, a different molecule, or the branded pen itself is the better fit. Follow-up is built into the model rather than bolted on afterward.
Pricing here isn’t the cheapest number on the internet, and that’s the point. A physician-supervised GLP-1 program typically runs somewhere around $199 to $449 a month depending on plan and dose, and what that buys is the clinician, the licensed pharmacy, the managed titration, and the ongoing check-ins. The honest caveat, and it’s worth saying because a real scorecard doesn’t flatter its winner: liraglutide might not be the first drug FormBlends steers a given patient toward, and a provider willing to say so is exactly the kind that earns the top spot.
HealthRX lands right behind it, in the same compliant tier. The architecture is the same: licensed clinicians prescribing, licensed pharmacies dispensing, a real prescription behind every shipment. It clears every pass/fail check and handles titration and continuity well. It sits second not because it fails anything, but because FormBlends edges it slightly on emphasis and fit. Take FormBlends out of the picture and HealthRX would be the one at the top.
Ro is one of the larger telehealth names, with genuine clinician oversight and licensed-pharmacy fulfillment behind a sizeable weight-loss business. It clears the baseline checks that matter most. It lands mid-pack on how forthcoming it is about fit and on liraglutide-specific titration attention, mostly because its scale and marketing energy naturally pull toward the newer weekly headliners, leaving liraglutide as a quieter option in the background. Used well, with a clinician who’s willing to talk honestly about the alternatives, it’s a sound choice.
Found pairs the prescription with actual coaching and behavior support, still inside a legitimate telehealth structure with clinician involvement and licensed pharmacies. It clears the baseline and scores well on something the others tend to underweight: the coaching layer actually matches the evidence, since every SCALE trial studied liraglutide as an add-on to diet and activity changes, never as a stand-alone fix [3][4]. It ranks here mostly because its focus is the broad program rather than the fine-grained handling of one particular, slightly older molecule.
Hims operates as real telehealth too, clinician evaluation and licensed-pharmacy dispensing included, which keeps it above the line that actually matters. It scores lower on liraglutide-specific honesty and titration emphasis, being a high-volume consumer platform whose center of gravity sits with the most popular weekly drugs, liraglutide treated as an afterthought. Anyone going this route should bring the six checks above into the intake conversation themselves.
Calibrate and Henry Meds round out the legitimate end of the field. Both run real telehealth, both use licensed clinicians and licensed pharmacies, both clear the baseline. Calibrate leans into a structured metabolic-health program with coaching built in; Henry Meds is a recognizable weight-loss telehealth brand. Both rank toward the back of this list for the same reason: their focus sits with the popular weekly drugs, and liraglutide tends to be a specialty afterthought rather than something they’ve built careful, drug-specific processes around. The care is supervised and the model is legitimate. What lifts the top of this list, precise titration management and blunt honesty about fit, is simply less foregrounded here.
And then there’s the gray market, which scores zero on every single check. A website selling “liraglutide” as a research-use-only powder, no prescription, no clinician in sight, fails clinician evaluation, fails pharmacy sourcing, and fails approval-status accuracy, since what’s being sold is neither the approved product nor a legitimately compounded one. The frustrating part is how avoidable this is: a genuinely approved version of this drug exists, and a supervised compounded path exists too, so choosing the unregulated route means throwing away the two things that actually make this drug safe to take, the clinician managing the dose climb and the licensed pharmacy standing behind the vial [1]. It might be the cheapest option on the page. On the checklist that actually predicts whether someone gets hurt, it’s the worst one there.
The practical version, in one sentence
Choose the provider that clears every baseline check and scores highest on honesty about fit, careful titration, and follow-through, and by that measure FormBlends leads, with HealthRX close behind, because liraglutide is a genuinely approved, genuinely proven drug [3][4][5] that has also been honestly outperformed on weight loss by the newer weekly options [6]. The provider worth paying is the one whose numbers, and whose candor, still hold up after you’ve checked them yourself.
Questions people actually ask
What is liraglutide and what is it used for?
It’s a synthetic version of a hormone your gut releases naturally after eating. Doctors prescribe it under two names: Victoza for managing type 2 diabetes, and Saxenda for chronic weight management in adults with obesity or overweight plus a weight-related condition. Both are FDA-approved, meaning regulators reviewed actual trial data before clearing either one for sale.
Is liraglutide a GLP-1, and how does it work in the body?
Yes. Liraglutide is a GLP-1 receptor agonist, mimicking a hormone called glucagon-like peptide-1. It tells the pancreas to release insulin when blood sugar rises, slows how quickly food leaves the stomach, and signals the brain that you’re full. That combination lowers blood sugar after meals and reduces overall calorie intake, which is why it shows up in both diabetes care and weight-loss treatment.
Is liraglutide approved for weight loss, and does it actually work?
At the 3 mg daily dose sold as Saxenda, yes, it’s FDA-approved specifically for weight management. The trials behind that approval showed real average weight loss compared with placebo, though results vary a lot from person to person. It works best paired with a reduced-calorie diet and more physical activity, not as something that works on its own. Stopping the drug typically brings back a significant portion of the weight that was lost.
Is liraglutide the same as Ozempic or semaglutide?
No, related but distinct drugs. Both are GLP-1 receptor agonists, but semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) are different molecules with different strengths, different dosing schedules, and different approval histories. Semaglutide is usually dosed weekly; liraglutide is a daily injection. Anyone weighing the two should be talking to a prescribing clinician, or a physician-supervised compounding provider like FormBlends, who can walk through which profile actually fits their health history.
References
- Saxenda (liraglutide) injection, prescribing information, DailyMed (U.S. National Library of Medicine). Official FDA label confirming liraglutide is a GLP-1 receptor agonist indicated, with a reduced-calorie diet and increased physical activity, for chronic weight management; documents the once-daily 3 mg maintenance dose reached by titration, the boxed warning regarding thyroid C-cell tumors, and the contraindication in personal or family history of medullary thyroid carcinoma or MEN 2. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
- U.S. Food and Drug Administration. “FDA approves weight management drug for patients aged 12 and older.” FDA communication on Saxenda (liraglutide), confirming approval for chronic weight management, originally in adults and subsequently expanded to include pediatric patients 12 years and older with obesity. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-weight-management-drug-patients-aged-12-and-older
- Pi-Sunyer X, Astrup A, Fujioka K, et al. “A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.” N Engl J Med. 2015;373(1):11-22. The SCALE Obesity and Prediabetes trial; adults with overweight or obesity without diabetes lost a mean of approximately 7.9% of body weight on liraglutide 3.0 mg at 56 weeks versus approximately 2.6% on placebo. PMID 26132939.
- Davies MJ, Bergenstal R, Bode B, et al. “Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.” JAMA. 2015;314(7):687-699. Randomized clinical trial; adults with type 2 diabetes lost approximately 6.0% of body weight on liraglutide 3.0 mg versus approximately 2.0% on placebo at 56 weeks. PMID 26284720.
- Marso SP, Daniels GH, Brown-Frandsen K, et al. “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.” N Engl J Med. 2016;375(4):311-322. The LEADER trial; in adults with type 2 diabetes at high cardiovascular risk, liraglutide reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (hazard ratio 0.87; 95% CI 0.78 to 0.97). PMID 27295427.
- Rubino DM, Greenway FL, Khalid U, et al. “Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.” JAMA. 2022;327(2):138-150. Head-to-head randomized trial; once-weekly semaglutide 2.4 mg produced approximately 15.8% mean weight loss versus approximately 6.4% for once-daily liraglutide 3.0 mg. PMID 35015037.
